Published on UCD National Virus Reference Laboratory (https://nvrl.ucd.ie)

Home > Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R
posted by Anonymous on 05 April 2016

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.
Clin Infect Dis. 2016 Jul 1;63(1):122-32

doi: 10.1093/cid/ciw207. 

UCD National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, D04 E1W1, Ireland    Tel: +353 1 7164401, Email: nvrl@ucd.ie

UCD Homepage | Gaeilge | Privacy | Disclaimer | Freedom of Information | Acceptable Use Policy

Source URL:https://nvrl.ucd.ie/node/200